



Meeting of the Risk Communication Advisory Committee

March 6, 2018

FDA White Oak Campus, Building 31, the Great Room (Rm. 1503)
10903 New Hampshire Avenue, Silver Spring, MD 20993

AGENDA

The Risk Communication Advisory Committee will discuss communicating risk information about fetal effects in product labeling according to the Pregnancy and Lactation Labeling Rule (PLLR), perception of risk and factors important to patients and prescribers, and societal factors that impact treatment decisions, to effectively assist patients and prescribers to make informed decisions about use of prescription drugs and vaccines in pregnancy.

- | | | |
|------------|-----------------------------------|---|
| 9:00 a.m. | Call to Order and Opening Remarks | Susan J. Blalock, Ph.D., M.P.H.
Chair
Risk Communication Advisory Committee |
| | Administrative Announcements | Lee Zwanziger, Ph.D.
Designated Federal Officer
Risk Communication Advisory Committee
FDA |
| 9:10 a.m. | Open Public Hearing | |
| 9:30 a.m. | Clarifying Questions | |
| 10:00 a.m. | Committee Discussion | |
| 11:00 a.m. | Break | |
| 11:15 a.m. | Committee Discussion | |
| 12:30 p.m. | Adjournment | Susan J. Blalock, Ph.D., M.P.H.
Chair
Risk Communication Advisory Committee |